The road ahead for cervical cancer prevention and control.
暂无分享,去创建一个
[1] E. Unger,et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. , 2013, The Journal of infectious diseases.
[2] J. Hadler,et al. Declining Rates of High-Grade Cervical Lesions in Young Women in Connecticut, 2008–2011 , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[3] J. T. Cox,et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. , 2013, American journal of obstetrics and gynecology.
[4] Sarah E. Wilson,et al. Coverage from Ontario, Canada's school-based HPV vaccine program: the first three years. , 2013, Vaccine.
[5] M. Tonelli,et al. Recommendations on screening for cervical cancer , 2013, Canadian Medical Association Journal.
[6] Robert N. Anderson,et al. Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.
[7] E. Kliewer,et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. , 2012, Journal of the National Cancer Institute.
[8] S. Wacholder,et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. , 2012, Journal of the National Cancer Institute.
[9] Jack Cuzick,et al. New technologies and procedures for cervical cancer screening. , 2012, Vaccine.
[10] M. Schiffman,et al. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. , 2012, Vaccine.
[11] N. Sardesai,et al. Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses , 2012, Science Translational Medicine.
[12] R. Jacobson,et al. The clinician's guide to the anti-vaccinationists' galaxy. , 2012, Human immunology.
[13] J. Wardle,et al. Human papillomavirus vaccination and sexual behaviour: cross-sectional and longitudinal surveys conducted in England. , 2012, Vaccine.
[14] L. Paszat,et al. Cervical screening: a guideline for clinical practice in Ontario. , 2012, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
[15] M. Schiffman,et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012 .
[16] K. Barrios,et al. TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers , 2012, Cancer Immunology, Immunotherapy.
[17] P. Naud,et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine , 2012, Human vaccines & immunotherapeutics.
[18] M Arbyn,et al. Worldwide burden of cervical cancer in 2008. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] D. Ekwueme,et al. The cost-effectiveness of male HPV vaccination in the United States. , 2011, Vaccine.
[20] E. Franco,et al. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. , 2011, Preventive medicine.
[21] D. Lowy,et al. Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine , 2011, Journal of the National Cancer Institute.
[22] M. Boily,et al. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. , 2011, The Journal of infectious diseases.
[23] S. Wacholder,et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.
[24] Masha Fridman,et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study , 2011, The Lancet.
[25] E. Franco,et al. Optimizing technology for cervical cancer screening in high-resource settings. , 2011, Expert review of obstetrics & gynecology.
[26] K. Neuzil,et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. , 2011, JAMA.
[27] J. Peres. For cancers caused by HPV, two vaccines were just the beginning. , 2011, Journal of the National Cancer Institute.
[28] H. Jessen,et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.
[29] N. Muñoz,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.
[30] P. Castle,et al. Feasibility Study of a Human Papillomavirus E6 Oncoprotein Test for Diagnosis of Cervical Precancer and Cancer , 2010, Journal of Clinical Microbiology.
[31] A. Ferenczy,et al. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. , 2010, Sexual health.
[32] C. Wheeler,et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial , 2010, BMJ : British Medical Journal.
[33] E. Franco,et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial) , 2010, BMC Cancer.
[34] Ahmedin Jemal,et al. Declining Death Rates Reflect Progress against Cancer , 2010, PloS one.
[35] A. Anttila,et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. , 2009, Journal of the National Cancer Institute.
[36] F. Bray,et al. Trends of cervical cancer mortality in the member states of the European Union. , 2009, European journal of cancer.
[37] Robert Ball,et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. , 2009, JAMA.
[38] E. Franco,et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. , 2009, Archives of medical research.
[39] J. Cuzick,et al. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data , 2009, BMJ : British Medical Journal.
[40] M. Schiffman,et al. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline , 2009, Infectious Agents and Cancer.
[41] M. Porta. The improbable plunge. What facts refute reasons to expect that the effectiveness of HPV vaccination programs to prevent cervical cancer could be low? , 2009, Preventive medicine.
[42] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.
[43] M. Sherman,et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. , 2009, Gynecologic oncology.
[44] S. Rosso,et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. , 2008, The Lancet. Oncology.
[45] W. Prendiville,et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis , 2008, BMJ : British Medical Journal.
[46] Joakim Dillner,et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. , 2008, Vaccine.
[47] Stephen D Walter,et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.
[48] Diane Solomon,et al. Risk assessment to guide the prevention of cervical cancer. , 2007, American journal of obstetrics and gynecology.
[49] Daron G Ferris,et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.
[50] S. Kjaer,et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. , 2006, Cancer research.
[51] J. Cuzick,et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.
[52] S. Walter,et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST) , 2006, International journal of cancer.
[53] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[54] A. Tos,et al. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. , 2005, American journal of clinical pathology.
[55] David R. Scott,et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.
[56] Xavier Castellsagué,et al. Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.
[57] David R. Scott,et al. Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible , 2002, Journal of Clinical Microbiology.
[58] E. Franco,et al. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[59] E. Franco,et al. Human papillomavirus testing for primary screening of cervical cancer precursors. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[60] K. Kerlikowske,et al. Frequency of Cervical Smear Abnormalities Within 3 Years of Normal Cytology , 2000, Obstetrics and gynecology.
[61] J Hedlund,et al. Risky business: safety regulations, risk compensation, and individual behavior , 2000, Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention.
[62] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[63] P. Babb,et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. , 1999, BMJ.
[64] Adult vaccination coverage--United States, 2010. , 2012, MMWR. Morbidity and mortality weekly report.
[65] J. Dungan. Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine , 2012 .
[66] C. Wheeler,et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.
[67] H. Kitchener,et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.
[68] J. Leichliter,et al. Human papillomavirus vaccine and sexual behavior among adolescent and young women. , 2012, American journal of preventive medicine.
[69] Thomas C Wright,et al. The ATHENA human papillomavirus study: design, methods, and baseline results. , 2012, American journal of obstetrics and gynecology.
[70] Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. , 2011, MMWR. Morbidity and mortality weekly report.
[71] FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). , 2010, MMWR. Morbidity and mortality weekly report.
[72] J. Tota,et al. Invited Commentary Invited Commentary: Human Papillomavirus Infection and Risk of Cervical Precancer—Using the Right Methods to Answer the Right Questions , 2009 .
[73] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.
[74] B. Monk. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2007 .
[75] E. Franco,et al. Prospects for controlling cervical cancer at the turn of the century. , 2003, Salud publica de Mexico.
[76] Evan R. Myers,et al. Accuracy of the Papanicolaou Test in Screening for and Follow‐up of Cervical Cytologic Abnormalities: A Systematic Review , 2001 .
[77] American Society for Colposcopy and Cervical Pathology. , 2001, Journal of lower genital tract disease.